The extraction of polysaccharides from Pleurotus djamor was meticulously optimized through response surface methodology (RSM), a statistical and mathematical technique that models and analyzes problems in which several variables influence the response of interest. The researchers focused on maximizing polysaccharide yield by fine-tuning extraction parameters, including temperature, time, and solvent-to-material ratio. This approach not only improved extraction efficiency but also ensured reproducibility, vital for scaling up and industrial applications.

Preliminary structural characterization of the isolated polysaccharides revealed a complex carbohydrate architecture, primarily composed of β-glucans, which are known for their biological activities. Advanced spectroscopic analyses suggested the presence of pyranose rings and glycosidic linkages fundamental to their bioactivity. Understanding this structural complexity is crucial as it influences the polysaccharides’ interaction with biological systems, thereby dictating their functional properties.

One of the standout aspects of this research is the demonstration of antioxidant potential, indicating the capability of the polysaccharides to scavenge free radicals and reduce oxidative stress. Oxidative stress is implicated in a myriad of chronic diseases and aging processes; hence, natural antioxidants serve as a pivotal intervention. The Pleurotus djamor polysaccharide’s antioxidant capacity suggests its utility in mitigating oxidative damage at the cellular level, which could translate into preventive strategies for degenerative diseases.

Equally significant is the immunomodulatory effect, characterized by the polysaccharide’s ability to modulate immune responses. The study highlighted the stimulation of macrophages and enhancement of cytokine production, which are vital mechanisms for innate immune defense. This immunomodulatory property reflects the therapeutic potential of Pleurotus djamor in enhancing host immunity, especially relevant in immunocompromised conditions or infections.

Antitumor activity was another critical focal point of the research. The polysaccharide demonstrated inhibitory effects on the proliferation of cancer cells, inducing apoptosis and arresting cell cycles. Such bioactivity indicates a promising natural compound capable of complementing conventional cancer therapies. The specificity and mechanism of action, possibly through modulation of signaling pathways and immune enhancement, merit further detailed investigation.

The intersection of extraction optimization and biomedical potential in this study highlights a comprehensive approach toward functional food and drug development. By integrating advanced statistical methodologies with bioactivity assays, the research sets a benchmark for future studies aiming to harness fungal polysaccharides for health applications. This holistic view bridges the gap between natural product chemistry and clinical relevance.

Moreover, the sustainable sourcing of Pleurotus djamor, a widely cultivable mushroom, enhances the feasibility of this polysaccharide as an accessible bioresource. The mushroom’s ease of cultivation under controlled conditions guarantees a consistent supply of bioactive compounds, essential for pharmaceutical standardization. This aligns with the growing global demand for sustainable and natural health products, minimizing the environmental footprint compared to synthetic analogs.

The study also emphasizes the importance of interdisciplinary collaboration, involving mycologists, biochemists, and pharmacologists, to decode the full potential of mushroom-derived polysaccharides. Such synergy accelerates the translation of laboratory findings into practical health solutions and functional foods. This collaborative approach is a key driver in the evolving landscape of natural product research.

Furthermore, the potential for these polysaccharides to be incorporated into dietary supplements or fortified foods opens new avenues for preventive health strategies. Given the rising incidence of chronic diseases linked to oxidative stress and immune dysfunction, integrating Pleurotus djamor polysaccharides into daily nutrition could offer a proactive defense mechanism. The consumer trend toward natural and plant-based products further supports this integration.

The robustness of response surface methodology in optimizing extraction conditions also signifies a methodological advancement in bioactive compound isolation. This statistical tool reduces experimental runs, conserves resources, and enhances the precision of extraction processes. Its application in this study serves as a template for other researchers working with plant and fungal metabolites, advocating for data-driven process refinement.

In the broader scientific and commercial context, these findings fuel the interest in mushroom polysaccharides as versatile agents with multifunctional health benefits. The demonstrated antioxidant, immunomodulatory, and antitumor activities collectively position Pleurotus djamor polysaccharides as candidates for pharmaceutical formulations, functional foods, and cosmetic products focused on health and wellness.

The translation of these findings into clinical trials will be essential to validate efficacy and safety in human populations. Future research should focus on detailed molecular mechanisms, bioavailability, dosage optimization, and synergistic effects with existing therapeutics. Such studies will pave the way for regulatory approvals and market introduction, bridging the gap from the lab bench to bedside.

Critically, this research underscores the untapped potential of fungi in drug discovery and nutrition science. While mushrooms have long been valued for their nutritional and medicinal properties, modern techniques and rigorous scientific validation are unlocking new dimensions of their utility. Pleurotus djamor’s bioactive polysaccharides exemplify this paradigm shift, offering a blueprint for sustainable and effective natural therapeutics.

This investigation sets a compelling precedent for the integration of traditional knowledge and cutting-edge science, fostering innovation in natural health product development. It invites a reevaluation of natural resources, urging scientists and industry stakeholders to harness biodiversity systematically. The journey from mushroom cultivation to molecular bioactivity profiles charts a promising course for future health interventions.

In conclusion, the study of polysaccharides from Pleurotus djamor using response surface methodology for extraction optimization delivers profound insights into natural compound science. The confirmed antioxidant, immunomodulatory, and antitumor potentials not only expand the horizons of functional food research but also illuminate pathways for new therapeutic agents rooted in nature. As the quest for safer, natural, and effective health solutions intensifies, Pleurotus djamor polysaccharides stand at the frontier of this transformative field.

Subject of Research: Polysaccharides extracted from the Pleurotus djamor mushroom, focusing on extraction optimization, structural analysis, and evaluation of antioxidant, immunomodulatory, and antitumor activities.

Article Title: Polysaccharide from Pleurotus djamor: extraction optimization with response surface methodology, preliminary structure, antioxidant, immunomodulatory and antitumor potentials.

Article References:
Govindan, S., Durairaj, J., Rajendran, G. et al. Polysaccharide from Pleurotus djamor: extraction optimization with response surface methodology, preliminary structure, antioxidant, immunomodulatory and antitumor potentials. Food Sci Biotechnol (2026). https://doi.org/10.1007/s10068-025-02085-6

Image Credits: AI Generated

DOI: 13 January 2026

This exploratory, randomized pilot study, conducted across multiple centers, sought to assess the safety and immunomodulatory effects of BJIKT—a well-known herbal remedy used traditionally in East Asian medicine for its anti-inflammatory and fatigue-relieving properties. The study specifically targeted patients with advanced NSCLC receiving atezolizumab monotherapy, an anti-PD-L1 checkpoint inhibitor widely used in clinical oncology. By integrating this herbal medicine with modern immunotherapy, the researchers aimed to explore if BJIKT could mitigate some common treatment-related adverse events such as fatigue and muscle wasting, while potentially enhancing immune activation.

The trial enrolled 28 patients who were randomly assigned to receive either BJIKT or a placebo, with both groups continuing standard atezolizumab therapy. Throughout the study, the team meticulously monitored adverse events (AEs), immune-related adverse events (irAEs), fatigue levels, and the progression of muscle loss, aiming to uncover interactions between the herbal treatment and immune checkpoint blockade. Beyond clinical symptomatology, a subset of patients underwent detailed immune profiling to shed light on the cellular immune mechanisms potentially influenced by BJIKT.

Findings revealed that adverse events were prevalent in over half of participants, a not unexpected outcome given the aggressive nature of cancer immunotherapy. Intriguingly, the BJIKT group exhibited a higher incidence of AEs (64.29%) compared to the placebo group (42.86%), though the majority of these events were mild to moderate and resolved by the conclusion of the trial. This raises important safety considerations but also underscores the complex interplay between herbal compounds and immune modulation therapies, warranting further pharmacovigilance in larger cohorts.

From an efficacy standpoint, the objective response rate (ORR) and disease control rate (DCR) were numerically higher in the BJIKT-treated group—16.67% versus 8.33% for ORR and 41.67% versus 25% for DCR compared to placebo—though these differences did not reach statistical significance. These encouraging trends suggest that BJIKT might augment tumor growth control during ICI therapy, possibly by enhancing the host immune system’s anti-tumor prowess. Nonetheless, the lack of statistical significance tempers overenthusiasm and highlights the exploratory nature of this pilot trial.

One of the more compelling aspects of the study lies in its immunological analyses. The researchers detected a significant reduction in PD-1 positive CD8+ T cells in patients receiving BJIKT, implying a decrease in T cell exhaustion—a state where T cells become less functional due to chronic antigen exposure, commonly seen in cancer. This finding indicates that BJIKT may reinvigorate cytotoxic T cells, a pivotal cell population responsible for directly attacking tumor cells. Conversely, while PD-1+ CD4+ T cell numbers also declined with BJIKT, this change was not statistically significant, suggesting a selective modulation of T cell subsets.

Beyond T cells, a notable increase in natural killer (NK) cell counts was observed in the BJIKT group. NK cells constitute an essential arm of innate immunity, capable of recognizing and destroying cancer cells without prior sensitization. The elevation of these effector cells may reflect enhanced innate immune surveillance facilitated by BJIKT, potentially contributing to improved tumor control in NSCLC. Moreover, immune profiling revealed trends toward increased activation of CD4+ T cells and the overall proportion of CD3+CD4+ cells, indicating a broader stimulation of helper T cell-mediated immune orchestration during treatment.

BJIKT’s capacity to alleviate fatigue and muscle loss—common debilitating symptoms experienced by patients undergoing immunotherapy—was also examined. While the herbal treatment showed a trend toward mitigating these symptoms, the changes were not statistically significant. Still, these observations correlate with BJIKT’s traditional use in managing fatigue and chronic inflammation, suggesting it may hold supportive care value for NSCLC patients in future integrative oncology frameworks.

The study’s design as a randomized, placebo-controlled pilot trial provides valuable preliminary insights but naturally comes with limitations inherent to small sample sizes, which restrict the statistical power to detect definitive effects. However, the findings lay a foundation for subsequent larger-scale investigations to validate BJIKT’s immunomodulatory benefits and safety profile in combination with ICIs. Such follow-up trials could also dissect the molecular pathways involved, potentially revealing novel complementary mechanisms by which traditional herbal medicine synergizes with cutting-edge immunotherapies.

Notably, the interplay between BJIKT and the complex tumor-immune microenvironment highlights the exciting potential of combining phytochemicals with immuno-oncological agents. This fusion of ancient herbal wisdom with modern molecular oncology could pave the way for innovative, multi-modal cancer treatment regimens aimed at boosting efficacy while minimizing toxicities. Furthermore, the selective immune effects observed with BJIKT—specifically the reduction of immune exhaustion markers and augmentation of NK cells—underscore the importance of immune homeostasis in achieving sustained anti-tumor responses.

From a clinical perspective, this research advocates for integrating complementary therapies like BJIKT into the multidisciplinary care of NSCLC patients receiving ICIs. Positive modulation of immune function and alleviation of adverse symptom burden could improve patient adherence to therapy and quality of life. However, the necessity for rigorous validation studies, standardized herbal preparations, and mechanistic elucidations cannot be overstated before broad application.

Additionally, the trial was registered with the Clinical Research Information Service of Korea, ensuring adherence to ethical and methodological standards. Such transparency not only bolsters credibility but also facilitates collaboration, data sharing, and global efforts to refine cancer therapies. Future studies may build upon this pilot trial to design adaptive, biomarker-driven approaches targeting immune exhaustion and enhancing effector cell function in NSCLC and beyond.

In summary, this pioneering research sheds light on the prospective role of Bojungikki-Tang as an adjunctive agent capable of finely tuning the immune landscape in NSCLC patients undergoing atezolizumab therapy. While conclusive evidence remains forthcoming, the reported reductions in immune exhaustion markers and elevations in innate immune effectors inspire optimism for harnessing herbal pharmacology in the fight against lung cancer. This convergence of traditional medicine and immuno-oncology represents a fertile frontier warranting enthusiastic scientific pursuit.

As the oncology community continues to grapple with the challenges of maximizing immunotherapy benefit, findings like these energize the search for integrative strategies. Bojungikki-Tang’s ancient formula, reinterpreted through the lens of modern immune profiling, exemplifies how history may inform future breakthroughs. Clinical trials with larger cohorts, longer follow-up, and multi-omics analyses will be imperative to validate these preliminary signals and ultimately translate them into robust, patient-centered cancer care innovations.

Subject of Research: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors

Article Title: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study

Article References:
Ko, M.M., Na, S.W., Yi, J.M. et al. Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study. BMC Cancer 25, 1229 (2025). https://doi.org/10.1186/s12885-025-14629-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14629-4